Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 clinical trials

Studies by the year they started

71 studies that test it; most in 2009 (9)

Who runs them

Industry 25 · Other 46

Merck Sharp & Dohme LLC (20) · AIDS Malignancy Consortium (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Zagazig University (2) · Sanofi Pasteur, a Sanofi Company (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · University of Pittsburgh (2) · International Agency for Research on Cancer (1)

Often tested with

Tested in the same studies.

Human papillomavirus vaccine, L1 type 16, 18 (5) · Human Papillomavirus Recombinant Vaccine nonavalent (2) · Meningococcal Vaccines (1) · Adacel (1) · Sintilimab (1) · Vaccination (1)

Studies

Open first, then newest update. How each study uses Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 is read from its arms, and is right about nine times in ten.

Testing it · 71

• A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in ZambiaActive, not recruitingPhase 4International Agency for Research on CancerNCT07256912Written as quadrivalent HPV vaccine
• Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital WartsCompletedPhase 3University of PretoriaNCT02750202Written as Quadrivalent HPV vaccine
• Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)WithdrawnPhase 3Merck Sharp & Dohme LLCNCT00733122Written as Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
• A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)CompletedPhase 3Merck Sharp & Dohme LLCNCT03493542Written as V501
• A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young AdultsTerminatedPhase 1National Cancer Institute (NCI)NCT00798265Written as Gardasil
• Immunogenicity of HPV Vaccine in Immunosuppressed ChildrenCompletedPhase 3The University of New South WalesNCT02263703Written as Quadrivalent HPV vaccine
• Vaccine Therapy in Preventing HPV in HIV-Positive Women in IndiaCompletedPhase 1AIDS Malignancy ConsortiumNCT00667563Written as quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
• Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive AdolescentsCompletedPhase 4University of WashingtonNCT05435209Written as Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
• Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 InfectionCompletedPhase 2AIDS Malignancy ConsortiumNCT00513526Written as Gardasil
• Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in IndiaActive, not recruitingPhase 4Partha BasuNCT00923702Written as Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)
• Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)CompletedPhase 3Merck Sharp & Dohme LLCNCT00380367Written as Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
• Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital WartsStatus unknownNot applicableZagazig UniversityNCT05761002Written as the Quadrivalent Vaccine (Gardasil)
• Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)CompletedPhase 4University Hospital, GhentNCT01914367Written as Gardasil
• Gardasil Versus Cervarix in the Treatment of WartsCompletedPhase 3Zagazig UniversityNCT05383625Written as Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
• ICI-VPH: Impact of HPV Immunisation Schedules Against HPVCompletedPhase 3CHU de Quebec-Universite LavalNCT02009800Written as Quadrivalent HPV vaccine
• Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT02199691Written as GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
• Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®CompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT02993757Written as Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
• Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected ChildrenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00339040Written as Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)
• Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected WomenCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00604175Written as Quadrivalent HPV vaccine
• Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and WomenCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT01461096Written as Quadrivalent HPV Vaccine

See all 71 studies that test Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 →